TNGXTango Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $62M
- 48% YoY
- Operating margin
- -178.4%
- 48% YoY
- EBITDA
- −$109M
- 24% YoY
- Market cap
- $3.8B
- Employees
- 137
- $455K revenue each
- Net debt / EBITDA
- —
- AI in 10-K
- 3.6
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 2 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$3M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes42% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentYes80% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo$455K · 53rd pctBottom quartile of its SIC industry
- Quiet on AINo3.6 per 10K words · 75th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$3.8B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$8M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $37M | $25M | $37M | $42M | $62M | 48% |
| Operating income | −$58M | −$111M | −$114M | −$146M | −$111M | 24% |
| Net income | −$58M | −$108M | −$102M | −$130M | −$102M | 22% |
| Operating cash flow | −$60M | −$109M | −$118M | −$132M | −$139M | 5.6% |
| Capex | $2M | $8M | $2M | $754K | $1M | 39% |
| Stock-based comp | $8M | $14M | $19M | $29M | $26M | 8.5% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Feb 10, 2026 | Third Rock Ventures IV, L.P. | SCHEDULE 13D/A | 4.7% | Passive |
| Nov 21, 2025 | Third Rock Ventures IV, L.P. | SCHEDULE 13D/A | 5.8% | Passive |
| Nov 14, 2025 | Third Rock Ventures IV, L.P. | SCHEDULE 13D/A | 7.0% | Passive |
| Jan 2, 2025 | BCTG Holdings, LLC | SCHEDULE 13D/A | 10.0% | Passive |
| Nov 7, 2024 | Boxer Capital Management, LLC | SC 13D/A | 6.5% | Passive |
| Oct 28, 2024 | Boxer Capital Management, LLC | SC 13D/A | 6.5% | Passive |
| Oct 15, 2024 | Boxer Asset Management Inc. | SC 13D/A | 0.0% | Passive |
| Oct 15, 2024 | Boxer Capital, LLC | SC 13D/A | 14.3% | Passive |
| Sep 4, 2024 | Third Rock Ventures IV, L.P. | SC 13D/A | 15.9% | Passive |
| Oct 18, 2023 | BCTG Holdings, LLC | SC 13D/A | 6.9% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $8M · 25
- Net
- −$8M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $10M | — | — |
| FY2024 | $7M | −$3M | — | — |
| FY2023 | $3M | $8M | — | — |